Keymed Biosciences Inc. (KEYMED BIO-B) has released its Monthly Return for Equity Issuer covering the period ended 31 March 2026, indicating a stable capital structure and adherence to Hong Kong Listing Rule public-float requirements.

Authorised Share Capital • Total authorised shares remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, keeping authorised capital steady at USD 50,000. No changes were recorded during the month.

Issued Shares and Treasury Position • Issued shares (excluding treasury shares) stood unchanged at 298.74 million. • The company held no treasury shares, and there were no issuances, cancellations, conversions, or repurchases during March.

Public Float Status • Keymed confirmed compliance with the Main Board’s minimum public-float threshold of 25% of issued shares as of 31 March 2026.

Corporate Actions • The company reported no movements related to share options, warrants, convertible securities, or other equity-linked instruments.

Governance Confirmation • The filing was authorised and submitted by Executive Director Dr. Bo Chen on 1 April 2026.

Overall, Keymed’s March return reflects a month of capital stability, with no dilution events and full compliance with Hong Kong Exchange regulations.